GPN Vaccines is developing a broad-spectrum vaccine against Streptococcus pneumoniae, which causes life-threatening pneumonia, meningitis, and sepsis, as well as otitis media in children. Up to two million deaths worldwide are attributed to S. pneumoniae each year, killing more children than AIDS, malaria and tuberculosis combined. The best vaccine available only protects against 20 of the 100 known strains. GPN Vaccines is therefore developing a novel, whole-cell vaccine to provide adults and children with broad-spectrum protection against S. pneumoniae, regardless of the strain.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for GPN Vaccine on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.